Journal of Clinical Oncology 2012
21 papers
In 2012, the Journal of Clinical Oncology emphasized research directions such as aligning clinical studies with patient-reported outcomes and closing the evidence-practice gap. A recurring theme involved quantifying medical value through incremental cost-effectiveness analysis. Clinical research focused heavily on molecular markers and targeted therapies across various malignancies. For instance, studies examined gene modules in breast cancer subtypes and the prognostic role of KRAS mutations in metastatic colorectal cancer.
Other work included the evaluation of dose-escalated radiation therapy for prostate cancer and the development of Tc-99m labeled small-molecule inhibitors for imaging metastatic disease. Research in lung adenocarcinoma explored the efficacy of erlotinib and the correlation of ERCC1 expression in circulating tumor cells with patient survival. Prolific contributors during this period included Everett E. Vokes, Martin J. Edelman, and Leslie L. Robison. Methodological papers also assessed the safety of research-related tumor biopsies in trials involving anti-angiogenic agents, reflecting a trend toward integrating molecular diagnostics and cost-utility metrics into clinical decision-making.
Top Authors
| Author | Papers |
|---|---|
| Jorge J. Nieva | 2 |
| Xiaofei Wang | 2 |
| Anobel Odisho | 1 |
| Benjamin Haibe-Kains | 1 |
| Bradford J Wood | 1 |
| Christopher Lum | 1 |
| Jared D. Acoba | 1 |
| Jianhua Chen | 1 |
| Søren Jensby Nielsen | 1 |
| Thórarinn Blöndal | 1 |